新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 投资 » 2020年全球性传播疾病(性病)检测市场将达到1670亿美元

2020年全球性传播疾病(性病)检测市场将达到1670亿美元

来源:生物谷 2014-12-05 13:22

2014年12月5日讯 /生物谷BIOON/ --性传播疾病(STD)也被称为性病(VD)或性传播感染(STI),是以性接触为主要传播方式的一组疾病。目前,已有多种方法被应用于性病的诊断检测。根据全球知名市场调研公司Research and Markets发布的报告,全球性传播疾病(STD)检测市场在2013年市值967亿美元,对应的检测容量为42.04亿,未来6年,全球STD检测市场将以8.5%的年度复合增长率(CAGR)快速增长,并在2020年将达到1674亿美元,对应的检测容量将达到55.2亿。

致命性STD发病率的上升带来了高额的经济负担,随之而来的是提供商发起的咨询与检测(PICT,指医务人员主动提供的咨询检测)及客户发起的咨询与检测(CICT,指患者主动提出的咨询检测),这些因素推动了全球STD检测市场的增长。然而,在落后地理区域(如西非国家)诸如实验室、设备、供应等基础设施的不足、缺乏训练有素的检测相关实验技术人员、自愿检测相关的耻辱感都可能成为全球STD检测市场发展的主要限制因素。不过,全球倡议及医疗基础设施的发展,将为市场的未来增长提供动力。

——按性病类型划分,全球STD诊断检测市场可细分为:衣原体检测、淋病检测、梅毒检测、人类免疫缺陷病毒(HIV)检测、单纯疱疹病毒(HSV)检测、人乳头瘤病毒(HPV)检测、软下疳检测。其中,HIV检测是第三大STD检测细分市场,在2014-2020预测期间内,年复合增长率(CAGR)将达到10.9%。

——根据检测地点划分,全球STD诊断检测市场可细分为:实验室检测和即时检验(POCT)。目前,无论从容量和收入计算,实验室检测均占据了主要份额,并将继续持有较大的市场份额。而即时检测在预测期内将保持恒定的速率增长。

——根据检测设备划分,全球STD诊断设备市场可细分为实验室检测设备和POC检测设备,其中,实验室检测设备在2013年市值为77亿美元,占据了大部分市场份额,在2014-2020预测期内,POC检测设备将以最快的速度增长。

——根据检测机构划分,正如前所述,许多医疗机构提供性病诊断检测服务,如专门的性病门诊、泌尿生殖医学(GUM)诊所及综合医院、政府实验室、私人诊断中心,这些机构是全球STD诊断检测市场的主要参与者。除了检测服务提供商,许多公司也提供检测设备,如实验室设备和POC检测试剂盒用于性病(STD)的诊断和检测,包括罗氏、生物梅里埃(BioMerieux)、Hologic、Becton Dickinson、雅培、丹纳赫、雅培、Bio-Rad等。

——根据地理区域划分,欧洲是最有利可图的市场之一。相对于其他地理区域而言,欧洲STD检测市场增长速度最快,2014-2020预测期内年复合增长率(CAGR)高达13.5%,并在2020年达到268亿美元。在亚太地区,由于HPV发病率较高,该地区HPV检测容量和收入将以更快的速度增长。(生物谷Bioon.com)

英文原文:Research and Markets: Global Sexually Transmitted Diseases (STDs) Testing Market 2013-2020 Disease Types, Testing Volume & Testing Devices Analysis of the $167 Billion Industry

The diagnostic testing market for sexually transmitted diseases is forecast to reach $167.4 billion by 2020, registering a CAGR of 8.5% during 2014-2020.

The growth in the market is chiefly attributed to the high growth in HIV and HPV testing, especially in Asia Pacific and African regions along with complementing growth rate of the European market.

Laboratory testing of STDs is significant, despite the presence of many Point-of-Care (PoC) testing kits available. Some of the STDs are not diagnosed with Point-of-Care methods. For instance, HSV (Herpes Simplex Virus), low-risk HPV (Human Papilloma Virus) and Chancroid, that manifest as "warts" on the patient's skin, require physical examination by the laboratory experts. Also, many of the PoC devices are not yet approved by the regulatory health authorities such as USFDA, owing to deviations in the sensitivity and specificity criteria. For these reasons, laboratory testing is considered to be the most reliable and globally accepted method for STD testing; therefore, it garners a comparatively larger market share than POC testing.

The report also provides market size and forecast for testing devices used for carrying such tests. The market for STD testing devices was valued at $7.7 billion in 2013, with laboratory testing devices accounting for most of the market, and PoC devices shall grow at the fastest rate.

Key findings of the study:

Global market for diagnostic testing of STDs is gaining traction with growth in HIV and HPV screening and laboratory testing

HIV testing market segment would grow at a CAGR of 10.9% during the forecast period

Europe would be one of the lucrative markets in terms of growth. The European STDs testing market would reach $26.8 billion by 2020, with highest CAGR of 13.5% (as compared to other regional markets)

HPV testing volume and revenue will grow at much faster rate owing to higher incidences in Asia Pacific region

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库